Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Tufts estimates that delayed market entry is worth approximately $500,000 in unrealized prescription drug or biologic sales per day, on average. Credit: Stock.Adobe.com/Arisa.

$500,000 Lost a Day: The Economics of Clinical Trial Execution Is Pharma's Expensive Secret

ByRichard Graham, PhD

August 3rd 2026

ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement

ByAndy Studna, Senior Editor

August 3rd 2026

© putilov_denis - © putilov_denis - stock.adobe.com

Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection

ByLauren Crooks, MSc, Greta Marie van Schoor, PhD, Anthony Everhart, MD, Bill Byrom, PhD, and Thijs Sondag

July 31st 2026

How to Prevent Continuous Data Review from Just Shifting the Manual Burden

ByRaviv Pryluk, PhD,Andy Studna, Senior Editor

July 31st 2026

ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access

ByAndy Studna, Senior Editor

July 31st 2026

Act Cover

Articles in this issue

Related Content

$500,000 Lost a Day: The Economics of Clinical Trial Execution Is Pharma's Expensive Secret

ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement

Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection

How to Prevent Continuous Data Review from Just Shifting the Manual Burden

ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access

Trending on Applied Clinical Trials Online

Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection

ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access

ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion

FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility

Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value